Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Postapproval Cardio Studies Challenged By Enrollment, Protocol Issues

This article was originally published in The Gray Sheet

Executive Summary

FDA’s assessments of strengths and weaknesses for eight years’ worth of completed cardiovascular trials show about one-third of studies are challenged by enrollment, protocol or bias issues, according to a graphical analysis by "The Gray Sheet."


Related Content

In Case You Missed It: Top 10 "Gray Sheet" Stories In November
Planning Board Proposes Postmarket Device Surveillance Timeline
Small Samples, Protocol Delays Mar FDA’s Use Of Postapproval Studies


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts